Paper Details

  1. Home
  2. Paper Details

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).

Author: BeckerJ-C, DougadosM, DurezP, EmeryP, GenantH K, LegertonC W, MitraP, OverfieldS, PeterfyC, QiK, VratsanosG, WesthovensR

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Abatacept delayed progression of UA/very early RA in some patients. It inhibited radiographic and MRI progression and this effect was maintained for 6 months after treatment stopped.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Several agents provide treatment for established rheumatoid arthritis (RA), but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA. OBJECTIVE: To determine the impact of T-cell costimulation modulation in patients with UA or ve...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927615/

データ提供：米国国立医学図書館（NLM）

Abatacept: A Promising Therapy for Early Rheumatoid Arthritis

This research delves into the complex world of rheumatoid arthritis (RA), a condition as challenging to treat as navigating a treacherous desert landscape. The authors conducted a double-blind, placebo-controlled trial to investigate the efficacy of abatacept, a medication that modulates T-cell costimulation, in delaying or preventing the progression of undifferentiated inflammatory arthritis (UA) or very early RA.

Abatacept: A Potential Tool for Early RA Intervention

This study, like a beacon of hope in the desert, offers promising results for the treatment of early RA. The researchers found that abatacept delayed the progression of UA/very early RA in some patients, reducing the development of RA by ACR criteria. This study highlights the potential of abatacept to intervene early in the disease course and potentially alter the trajectory of RA.

Targeting T-Cell Costimulation: A New Frontier in RA Treatment

This research, like a desert explorer uncovering a hidden oasis, reveals a new frontier in RA treatment. The authors' findings suggest that modulating T-cell costimulation with abatacept could offer a promising approach to delaying or preventing the progression of early RA. This study underscores the importance of understanding the underlying mechanisms of RA and developing targeted therapies to address these mechanisms.

Dr.Camel's Conclusion

This study is a testament to the progress being made in the field of RA treatment, like a desert traveler finding a new path to their destination. The authors' findings suggest that abatacept holds promise as a potential therapy for early RA, potentially altering the course of this debilitating condition. This research is a reminder that, through ongoing research and innovation, we can continue to find new and effective ways to treat RA and improve the lives of those affected by this disease.

Date :
  1. Date Completed 2010-06-08
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

19933744

DOI: Digital Object Identifier

PMC2927615

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.